Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary

Prime Medicine

06/08/2026 16:07

Prime Medicine, Inc. PRME.OQ reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -41 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -29 cents to -21 cents per share.
Revenue rose 3.5% to $1.15 million from a year ago; analysts expected $1.30 million. 
Prime Medicine, Inc.'s reported EPS for the quarter was a loss of 24 cents​.
The company reported a quarterly loss of $42.11 million.
Prime Medicine, Inc. shares had fallen by 16.5% this quarter and lost 11.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Prime Medicine, Inc. is $7.50, about 58.9% above its last closing price of $3.08
This summary was machine generated from LSEG data August 6 at 03:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.26
-0.24
Beat
Mar. 31 2026 
-0.25
-0.28
Missed
Dec. 31 2025 
-0.25
-0.26
Missed
Sep. 30 2025 
-0.25
-0.32
Missed